What is the recommended management for LCIS?

Lobular carcinoma in situ (LCIS) is considered a marker for increased risk of developing breast cancer rather than a direct precursor. Therefore, the management of LCIS focuses on surveillance and risk reduction. The recommended approach typically includes annual mammography to monitor for changes and the use of tamoxifen, which is an estrogen receptor modulator that helps reduce the risk of developing invasive breast cancer in women at high risk.

This strategy acknowledges the elevated risk associated with LCIS while balancing the need for vigilant monitoring and preventive measures. Annual mammograms allow for the early detection of any potential breast changes, and tamoxifen serves as a chemopreventive option that can further decrease the likelihood of future breast cancer development.

Other strategies, such as surgical removal of the area or chemotherapy, are not indicated in the standard management of LCIS, as the condition itself is not classified as cancer and does not typically require such aggressive interventions. Additionally, stating that no treatment is required does not reflect the importance of active monitoring and risk management associated with LCIS.